Pharmafile Logo
Pharmafocus logo
Advanced Search

lung disease

Showing 4 posts of 4 posts found.

Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug

May 12, 2023
Medical Communications Bellerophon Therapeutics, Cardiology, clinical trial, lung disease

US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed its phase 3 REBUILD study, …

News
17096650341_abceee54b5_z

Living in polluted city for ten years increases risk of lung disease as much as pack of cigarettes a day for 29 years

August 14, 2019
Research and Development Air pollution, COPD, lung disease, pharma emphysema, public health

Air pollution in cities dramatically increases the risk for and risk of progression of emphysema, a form of chronic obstructive …

News
bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …

News
Pfizer image

Pfizer gets first approval for rare lung disease

May 29, 2015
Sales and Marketing FDA, Pfizer, Rapamune, lung disease

Pfizer’s Rapamune will become the first drug available to treat the very rare lung disease lymphangioleiomyomatosis (LAM) after receiving approval …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024